Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic

Harvard Apparatus Regenerative Technology has treated the first patient with its Cellspan Esophageal Implant in a Phase 1 clinical trial at the Mayo Clinic in Rochester, Minnesota. The implant is designed to leverage the patient's regenerative capacity to treat severe esophageal diseases. The trial is a feasibility and safety study in up to ten patients under an FDA-approved IND, with primary and secondary endpoints to assess the establishment of a biological neoconduit and mucosal lining in the esophagus. The Cellspan Esophageal Implant consists of a modified polyurethane tubular mesh scaffold with live autologous adipose-derived Mesenchymal Stromal Cells. The Company has activated three clinical trial sites and plans to progress the trial to bring this innovative therapy to patients in need. The treatment represents a significant advancement in regenerative medicine and a potential alternative to conventional surgical reconstruction for esophageal disease.